Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer

NCT ID: NCT05297734

Last Updated: 2025-03-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

2996 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-06-24

Study Completion Date

2028-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This cluster-randomized comparative effectiveness trial compares a technology-based supportive cancer care (SCC) approach with a redesigned team-based supportive cancer care (SCC) approach.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

PRIMARY OBJECTIVES:

I. Greater intervention effects on health-related quality of life

SECONDARY OBJECTIVES:

I. Greater intervention effects on patient activation II. Greater satisfaction with care and decision-making III. Greater documentation of goals of care and symptoms IV. To lower acute care V. Greater palliative care and hospice

OUTLINE: Sites are randomized to 1 of 2 arms.

ARM A: Patients receive educational materials to assist with advance care planning and symptom management through a technology-based supportive cancer care weekly during months 1-4 and every other week during months 5-12.

ARM B: Patients are paired with a lay health worker who will discuss the same educational materials from ARM A either in person or by telephone discussions weekly during months 1-4 and every other week during months 5-12.

All participants complete a baseline interview upon enrollment during the initial consent phone contact and then a survey at 3-, 6-and 12-months post enrollment.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

End of Life Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Cluster Randomized Controlled Trial among 26 clinics
Primary Study Purpose

HEALTH_SERVICES_RESEARCH

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Technology-based supportive cancer care

Patients receive educational materials to assist with advance care planning and symptom management through a technology-based supportive cancer care weekly during months 1-4 and every other week during months 5-12.

Group Type ACTIVE_COMPARATOR

Receive technology-based supportive cancer care

Intervention Type OTHER

All participants will receive an electronic health record message or email with standardized information provided regarding advance care planning and symptom management.

Redesigned team-based supportive cancer care

Patients are paired with a health educator who will discuss the same educational materials from ARM A either in person or by telephone discussions weekly during months 1-4 and every other week during months 5-12.

Group Type EXPERIMENTAL

Receive redesigned team-based supportive cancer care

Intervention Type BEHAVIORAL

Lay Health Workers will meet with 1:1 with participants over 12 months to discuss advance care planning, surrogate decision-makers, advance directives and physician orders for life sustaining treatment.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Receive technology-based supportive cancer care

All participants will receive an electronic health record message or email with standardized information provided regarding advance care planning and symptom management.

Intervention Type OTHER

Receive redesigned team-based supportive cancer care

Lay Health Workers will meet with 1:1 with participants over 12 months to discuss advance care planning, surrogate decision-makers, advance directives and physician orders for life sustaining treatment.

Intervention Type BEHAVIORAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Technology-based SCC approach Patients Activated in Cancer care through Teams (PACT), Redesigned SCC team-based approach

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Newly diagnosed patients with solid tumor cancer diagnosis or recurrence of the disease.
2. Patients must have the ability to understand and willingness to provide verbal consent.
3. Participants must speak English, Spanish, Chinese, or Vietnamese.

Exclusion Criteria

1. Inability to consent to the study
2. Plans to change oncologist within 12 months
3. Employed by the practice site
4. Patients who anticipate moving from the area within 12 months
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Patient-Centered Outcomes Research Institute

OTHER

Sponsor Role collaborator

Stanford University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Manali Indravadan Patel

Assistant Professor of Medicine

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Alabama at Birmingham

Birmingham, Alabama, United States

Site Status RECRUITING

University of South Alabama

Mobile, Alabama, United States

Site Status RECRUITING

Beckman Research Institute of City of Hope

Duarte, California, United States

Site Status RECRUITING

VA Medical Center, Fresno

Fresno, California, United States

Site Status RECRUITING

Santa Clara Valley Medical Center

Fruitdale, California, United States

Site Status RECRUITING

St Jude Heritage Medical Group

Fullerton, California, United States

Site Status RECRUITING

Oncology Institute for Hope and Innovation

Los Angeles, California, United States

Site Status RECRUITING

Sacramento VA Medical Center - VA Northern California Health Care System

Mather, California, United States

Site Status ACTIVE_NOT_RECRUITING

Pacific Cancer Care

Monterey, California, United States

Site Status ACTIVE_NOT_RECRUITING

VA Palo Alto

Palo Alto, California, United States

Site Status ACTIVE_NOT_RECRUITING

Zuckerberg San Francisco General

San Francisco, California, United States

Site Status RECRUITING

Kaiser Foundation Research Institute

San Francisco, California, United States

Site Status RECRUITING

University of San Francisco

San Francisco, California, United States

Site Status RECRUITING

San Francisco VA Medical Center

San Francisco, California, United States

Site Status ACTIVE_NOT_RECRUITING

Spark M. Matsunaga VA Medical Center

Honolulu, Hawaii, United States

Site Status RECRUITING

North Las Vegas VA Medical Center

Las Vegas, Nevada, United States

Site Status ACTIVE_NOT_RECRUITING

George E. Wahlen Department of Veterans Affairs Medical Center

Salt Lake City, Utah, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Manali I Patel, MD MPH MS

Role: CONTACT

6507234000

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Gabrielle Rocque, MD

Role: primary

Jennifer Y Pierce, MD

Role: primary

Finly Zachariah, MD

Role: primary

800-826-4673

Sangeeta Aggarwal, MD

Role: primary

David Park, MD

Role: primary

Richy Agajanian, MD

Role: primary

Niharika Dixit, MD

Role: primary

Raymond Liu, MD

Role: primary

Kim Rhoads, MD

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

63646

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.